Correlation Between Madrigal Pharmaceuticals and PDS Biotechnology

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both Madrigal Pharmaceuticals and PDS Biotechnology at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Madrigal Pharmaceuticals and PDS Biotechnology into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Madrigal Pharmaceuticals and PDS Biotechnology Corp, you can compare the effects of market volatilities on Madrigal Pharmaceuticals and PDS Biotechnology and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Madrigal Pharmaceuticals with a short position of PDS Biotechnology. Check out your portfolio center. Please also check ongoing floating volatility patterns of Madrigal Pharmaceuticals and PDS Biotechnology.

Diversification Opportunities for Madrigal Pharmaceuticals and PDS Biotechnology

-0.61
  Correlation Coefficient

Excellent diversification

The 3 months correlation between Madrigal and PDS is -0.61. Overlapping area represents the amount of risk that can be diversified away by holding Madrigal Pharmaceuticals and PDS Biotechnology Corp in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on PDS Biotechnology Corp and Madrigal Pharmaceuticals is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Madrigal Pharmaceuticals are associated (or correlated) with PDS Biotechnology. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of PDS Biotechnology Corp has no effect on the direction of Madrigal Pharmaceuticals i.e., Madrigal Pharmaceuticals and PDS Biotechnology go up and down completely randomly.

Pair Corralation between Madrigal Pharmaceuticals and PDS Biotechnology

Given the investment horizon of 90 days Madrigal Pharmaceuticals is expected to generate 1.03 times more return on investment than PDS Biotechnology. However, Madrigal Pharmaceuticals is 1.03 times more volatile than PDS Biotechnology Corp. It trades about 0.21 of its potential returns per unit of risk. PDS Biotechnology Corp is currently generating about -0.27 per unit of risk. If you would invest  25,934  in Madrigal Pharmaceuticals on September 1, 2024 and sell it today you would earn a total of  6,885  from holding Madrigal Pharmaceuticals or generate 26.55% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

Madrigal Pharmaceuticals  vs.  PDS Biotechnology Corp

 Performance 
       Timeline  
Madrigal Pharmaceuticals 

Risk-Adjusted Performance

10 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in Madrigal Pharmaceuticals are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite quite uncertain technical and fundamental indicators, Madrigal Pharmaceuticals disclosed solid returns over the last few months and may actually be approaching a breakup point.
PDS Biotechnology Corp 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days PDS Biotechnology Corp has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

Madrigal Pharmaceuticals and PDS Biotechnology Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with Madrigal Pharmaceuticals and PDS Biotechnology

The main advantage of trading using opposite Madrigal Pharmaceuticals and PDS Biotechnology positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Madrigal Pharmaceuticals position performs unexpectedly, PDS Biotechnology can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in PDS Biotechnology will offset losses from the drop in PDS Biotechnology's long position.
The idea behind Madrigal Pharmaceuticals and PDS Biotechnology Corp pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.

Other Complementary Tools

My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Content Syndication
Quickly integrate customizable finance content to your own investment portal
USA ETFs
Find actively traded Exchange Traded Funds (ETF) in USA
Sign In To Macroaxis
Sign in to explore Macroaxis' wealth optimization platform and fintech modules
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments